Mode
Text Size
Log in / Sign up
N/A N=64 Randomized Single-blind Treatment

Needling Techniques for Knee Osteoarthritis

Knee Osteoarthritis · Kidney Yin Deficiency · Kidney Yang Deficiency

Enrolled (actual)
64
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: WOMAC Total in Week 15 — 11.6; 54.4 score on a scale — p=<0.001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Acupuncture (Procedure); Conventional Medical Treatment (Drug)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Svijetlana Perculija Durdevic
Primary completion
Dec 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
WOMAC Total in Week 15
11.6; 54.4 <0.001 sig
SECONDARY
WOMAC Pain in Week 15
2.4; 11.3 <.001 sig
SECONDARY
WOMAC Stiffness in Week 15
0.7; 4.6 <0.001 sig
SECONDARY
WOMAC Functional Disability in Week 15
8.6; 38.6 <0.001 sig
SECONDARY
VAS in Week 15
12.6; 61 <0.001 sig
SECONDARY
KDSQ in Week 15
10.8; 24.8 <0.001 sig
SECONDARY
DRUG in Week 15
96.0; 870.0 <0.001 sig
SECONDARY
Active Extension L and R Knees in Week 15
0.429; 0.42; 0.607; 0.714 0.8493
SECONDARY
Active Flexion L and R Knees in Week 15
94.1; 90.2; 96.1; 91.4 0.490
SECONDARY
Circumference of L and R Upper Leg in Week 15
55.3; 58.3; 58.7; 55.7 0.083
SECONDARY
Circumference of L and R Knees in Week 15
43.1; 41.8; 43.1; 41.8 0.341
SECONDARY
WOMAC Total in Week 24
20.4; 53.4 <0.001 sig
SECONDARY
WOMAC Pain in Week 24
4.5; 11 <.001 sig
SECONDARY
WOMAC Stiffness in Week 24
1.1; 3.4 <0.001 sig
SECONDARY
WOMAC Functional Disability in Week 24
14.7; 39.0 <0.001 sig
SECONDARY
VAS in Week 24
13.8; 59.5 <0.001 sig
SECONDARY
KDSQ in Week 24
13.9; 25.0 <0.001 sig
SECONDARY
DRUG in Week 24
184.0; 765.5 <0.001 sig
SECONDARY
Active Extension L and R Knee in Week 24
0; 0; 0; 0
SECONDARY
Active Flexion L and R Knees in Week 24
98.6; 99.5; 101.6; 99.8 0.953
SECONDARY
Circumference of L and R Upper Leg in Week 24
58.8; 57.2; 59.3; 57.2 0.261
SECONDARY
Circumference of L and R Knee in Week 24
43.6; 42.4; 44.0; 42.4 0.445
SECONDARY
WOMAC Total in Week 39
22.0; 18.2; 56.4; 57.3 <0.001 sig
SECONDARY
WOMAC Pain in Week 39
5.3; 4.7; 11.5; 11.7 <0.001 sig
SECONDARY
WOMAC Stiffness in Week 39
1.2; 1.2; 3.8; 4.2 <0.001 sig
SECONDARY
WOMAC Functional Disability in Week 39
15.5; 12.3; 40.8; 41.9 <0.001 sig
SECONDARY
VAS in Week 39
18.3; 28.0; 59.5; 59.1 <0.001 sig
SECONDARY
KDSQ in Week 39
14.6; 14.8; 27.2; 26.2 <0.001 sig
SECONDARY
DRUG by Added Assessment in Week 39, Crossover Part
276.1; 319.6; 637.5; 625.0 0.204
SECONDARY
Lequesne Index in Week 24, Between-group Analysis
5.1; 12.63 < 0.001 sig

Summary

The thirty-nine-week open-label clinical study investigates the efficacy of acupuncture for Knee Osteoarthritis (KOA) as adjunctive therapy to analgesics compared to analgesics only and assesses the effects after 9 and 24 weeks, with safety assessment provided. The study seeks to find possible additional benefits of acupuncture on Kidney Deficiency (KD) while treating KOA with an acupuncture protocol designed to treat KOA following Traditional Chinese Medicine (TCM) theory, which connects KOA with KD as its root cause. The points prescription uses local and Kidney-related points to treat KOA. The chronic conditions require a higher number of acupuncture treatments. This study will provide acupuncture treatments in three cycles, each three weeks long, with frequency three times weekly. Twenty-seven acupuncture treatments of KOA during fifteen weeks tend to improve KOA and KDS; symptoms are assessed in 10 successive time points, and treatment effects and effect persistence are analysed. 64 patients with symptomatic KOA are randomly allocated into the Acupuncture (A) or Control (C) group according to their permanent, unique, and coincidental Personal Identification Number, which is randomly given to all citizens in Croatia. Before the experiment starts, demographics and disease parameters of all participants are compared. To objectify acupuncture effects, the enrolled physiatrist's measures included knee measures at 3 time points: baseline, at the end of acupuncture (Week 15), and nine weeks later (Week 24). Subjective evaluations of symptoms are assessed by Western Ontario and McMaster University Arthritis Index (WOMAC) total and subscales scores, Numeric Rating Scale (NRS), and Kidney Deficiency Syndrome Questionnaire (KDSQ) every 3 weeks till the 24th week (9 assessments). Analgesics taken by participants (DRUG) in the last three days before the assessments are recorded. Acupuncture treatment was promised to all participants. Therefore, at Week 25, the between-group analysis ended, and the C group crossed over to receive the identical acupuncture protocol. The 10th assessment in Week 39 was used to estimate, by within-group analysis, the immediate effects of the acupuncture in group C and the effect persistence in group A. The Lequesne index was introduced additionally at Week 24 as another measure of the knee's functional state.

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of Knee Osteoarthritis
  • Knee Osteoarthritis for at least 6 months
  • painful knee in last month
  • radiographic changes of the knee (Kellgren-Lawrence grade 2 or more)
  • signed informed consent
  • participant can move independently

Exclusion Criteria

  • if the participant got knee intra-articular injection 3 months before his entry into the study
  • uncontrolled malignant disease
  • unstable heart disease
  • advanced organ failure disease (NYHA III or IV, or a more than the twofold increase of creatinin, or marked dyspnea)
  • unstable psychiatrist's disease
  • bleeding diathesis
  • anticoagulant use
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05014542). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search